ReSolution Rhodococcus Equi Antibody

Please login to view pricing.

ReSolution Rhodococcus Equi Antibody is the only licensed R. equi Antibody with published data in controlled challenge studies demonstrating efficacy as an aid in the control of Rhodococcus equi. Our research showed that the administration of ReSolution within the first three days of life increased VapA (Virulence-Associated Plasmid A) titers for R. equi pneumonia. VapA is a lipoprotein expressed at the surface of R. equi and is necessary for virulence of disease. Rhodococcus Equi Antibody high in VapA means reduced severity of disease in foals. Administration of one liter of ReSolution early in life reduced, statistically, the severity of radiographic lung lesions after infection and reduced morbidity attributable to infection with R. equi.

A study was recently conducted by the Gluck Equine Research Center that evaluated commercial R. equi antibody products (Sanz et al). The study evaluated the distribution of VapA-specific IgG and IgG subclasses in commercially available products. ReSolution Rhodococcus Equi Antibody showed to be statistically significantly higher than competitor’s products (with a p-value < 0.05) when VapA-specific IgGa levels were measured (4x higher!).

At Mg Biologics we’ve developed a VapA potency test for our product and all our serials have a minimum release titer of 1:10,000 (as published by Caston et al). This study confirms that with minimum VapA titer levels at 1:10,000, Mg’s ReSolution is the top performer regarding VapA Rhodococcus Equi Antibody.

Caston, S. S., McClure, S. R., Martens, R. J., Chaffin, M. K., Miles, K. G., Griffith, R. W., & Cohen, N. D. (2006). Eect of hyperimmune plasma on the severity of pneumonia caused by Rhodococcus equi in experimentally infected foals. Veterinary Therapeutics: Research in Applied

Veterinary Medicine, 7(4), 361–375.

Sanz, M. G., Oliveira, A. F., Page, A., & Horohov, D. W. (2014). Administration of commercial R. equi specific hyperimmune plasma results in variable amounts of IgG against pathogenic bacteria in foals. Veterinary Record. doi:10.1136/vr.102594